Insmed Analyst Ratings
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Insmed's Brensocatib Poised for Market Leadership: A Buy Rating Amidst Unthreatening Competition
Buy Rating Affirmed for Insmed on Breakthrough Trials and Market Expansion Opportunities
Insmed Analyst Ratings
Truist Financial Reaffirms Their Buy Rating on Insmed (INSM)
Brensocatib Poised for Market Success: A Buy Rating for Insmed Amid Positive KOL Sentiment and Limited Competition
Insmed (INSM) Receives a Buy From Morgan Stanley
Insmed Analyst Ratings
Insmed's Promising Outlook: Buy Rating Backed by Arikayce Performance and Brenso Launch Potential
Strong Arikayce Sales and Promising Clinical Advancements Bolster Buy Rating for Insmed
Insmed Analyst Ratings
Barclays Keeps Their Buy Rating on Insmed (INSM)
Goldman Sachs Raises Price Target on Insmed to $102 From $74, Maintains Buy Rating
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $102
Insmed Analyst Ratings
HC Wainwright Adjusts Price Target on Insmed to $90 From $70, Maintains Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: CureVac (CVAC), Insmed (INSM) and Quest Diagnostics (DGX)
Insmed (INSM) Receives a Buy From Evercore ISI
Insmed Analyst Ratings